MedTrace Logo

Registry of Autoimmune Interstitial Lung Disease

NCT05365009 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-05-06

No results posted yet for this study

Summary

Interstitial lung diseases (ILD) constitute a group of entities characterized by inflammation and/or fibrosis of the lung parenchyma.

In recent years, with the advent of new diagnostic tools and therapeutic options, multidisciplinary evaluation is essential, since it optimizes the interpretation of each case and the quality of care for these pathologies Consensus for the identification and management of ILD associated with SSc (ILD-SSc) is the only guideline published at present. In the others autoimmune ILD (Ai-ILD), screening, diagnosis, treatment and follow-up strategies are usually performed according to the criteria of the treating medical team. Guidelines regarding the follow-up and indication of immunosuppressive and antifibrotic treatment are lacking. Many questions on the horizon of the Ai-ILD should be answered as better quality evidence emerges from studies with a greater number of patients and better methodological design.

Conditions

  • Interstitial Lung Disease Due to Systemic Disease

Interventions

DIAGNOSTIC_TEST

Multidisciplinary aproach

regular tests

Sponsors & Collaborators

  • Sociedad Argentina de Reumatologia

    collaborator OTHER

  • EPIMAR registry

    lead NETWORK

Principal Investigators

  • Florencia Vivero, MD · Sociedad Argentina Reumatologia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-10
Primary Completion
2023-04-30
Completion
2027-10-31

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05365009 on ClinicalTrials.gov